Arno Therapeutics has appointed Joseph Bisaha as its new VP of clinical operations and project management and David Jackson as its VP of diagnostics. In their new positions, both Bisaha and Jackson will support the development of the personalized cancer drug onapristone, Arno's lead product.
Before joining Arno, Bisaha was a clinical research consultant with Kaizen Clinical Services, where he handled Arno's clinical Operations and project management activities. During his 17-year career, he has held various management roles, including associate VP of project management at ImClone Systems and senior director of clinical research and drug development at Ono Pharma.
Jackson comes to Arno from molecular testing firm PrimeraDx where he was VP of business development. Jackson also was senior director of companion diagnostic partnerships at Qiagen Manchester and consulted drug and diagnostics developers on the development and commercialization of personalized medicines and companion tests.